Metrics to compare | FBLG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFBLGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.2x | −5.4x | −0.4x | |
PEG Ratio | 0.00 | 1.26 | 0.00 | |
Price/Book | 1.8x | 4.2x | 2.6x | |
Price / LTM Sales | - | 17.2x | 3.0x | |
Upside (Analyst Target) | - | 89.2% | 49.1% | |
Fair Value Upside | Unlock | 1.9% | 6.3% | Unlock |
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.